The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Modified chemotherapy for pediatric patients with Down syndrome and high-risk B-ALL
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke with Karen Rabin, Texas Children’s Hospital, Houston, US. We asked, Can modified chemotherapy regimens improve outcomes for pediatric patients with Down syndrome and high-risk B-ALL?
Modified chemotherapy for pediatric patients with Down syndrome and high-risk B-ALL
Rabin highlights the poor historical outcomes for patients with Down syndrome, including an increased risk of relapse and treatment-related mortality. The prior Children’s Oncology Group trial AALL0232 (NCT00075725) was terminated due to excessive treatment-related mortality due to sepsis and profound neutropenia.
Rabin then discusses data from the recent AALL1131 trial (NCT02883049) investigating a modified chemotherapy regimen to increase safety and improve outcomes; modifications included changing four-drug to three-drug induction, leucovorin rescue after intrathecal methotrexate, modified intravenous methotrexate during interim maintenance, and enhanced supportive care guidelines.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
